Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

From:
Department for International Development
Published
1 January 2009
Document Type:
Journal Article
Theme:
Health
Authors:
Burton, D.R., Koff, W.C., Poignard, P., Simek, M.D., Walker, L.M., Fling, S., Hammond, P.W., Mitcham, J.L., Moyle, M., Olsen, O.A., Po-Ying Chan-Hui, Wrin, T., Phogat, S.K., Frey, S.M., Goss, J.L., Kaminsky, S., Lehrman, J.K., Phung, P., Priddy, F.H., Wagner, D., Zamb, T.

Abstract

Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1–infected individuals, define critical epitopes for HIV vaccine design. Using a systematic approach, we have examined neutralization breadth in the sera of about 1800 HIV-1–infected individuals, primarily infected with non–clade B viruses, and have selected donors for monoclonal antibody (mAb) generation. We then used a high-throughput neutralization screen of antibody-containing culture supernatants from about 30,000 activated memory B cells from a clade A–infected African donor to isolate two potent mAbs that target a broadly neutralizing epitope. This epitope is preferentially expressed on trimeric Envelope protein and spans conserved regions of variable loops of the gp120 subunit. The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses.

Citation

Science (2009) 326 (5950) 285-289 [DOI: 10.1126/science.1178746]

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

Updates to this page

Published 1 January 2009
Contents